Product Details
Lenvima
Lenvatinib8 mg/Dose
Capsule
8-mg Daily-Dose Pack
DIN/PIN/NPN
02468220
Manufacturer
Eisai Limited
Formulary Listing Date
2023-04-28
Unit Price
70.7752
Amount MOH Pays
70.7752
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EX08
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Lenvatinib
For the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) who meet ALL the following criteria:
Exclusion criteria:
Duration of Approval: 1 Year Renewal of funding will be considered until a patient progresses on treatment or develops unacceptable toxicity to Lenvatinib. Duration of Approval: 1 Year For the treatment of unresectable advanced1 hepatocellular carcinoma (HCC) in adult patients who meet ALL the following criteria prior to starting treatment with Lenvatinib:
1Patients with Stage B HCC, based on the Barcelona Clinic Liver Cancer (BCLC) Staging System will be considered for lenvatinib if they have progressed on transarterial chemoembolization (TACE). Case-by-case consideration will be provided for Stage B HCC patients who are not suitable for the TACE procedure. In such situations, please provide additional information to support why the patient is not suitable for TACE. Exclusion Criteria: Patients meeting any of the following criteria will not be funded.
Only one of sorafenib or lenvatinib for the treatment of HCC will be funded in the first line. Patients will be permitted to switch from sorafenib to lenvatinib if they experience intolerance and have not progressed on sorafenib. Recommended Dosage: Renewal Criteria: Approval duration for initials and approvals: 3 months EAP Drug Request Form: |